Your browser doesn't support javascript.
loading
Differences in the Presentation and Progression of Parkinson's Disease by Sex.
Iwaki, Hirotaka; Blauwendraat, Cornelis; Leonard, Hampton L; Makarious, Mary B; Kim, Jonggeol J; Liu, Ganqiang; Maple-Grødem, Jodi; Corvol, Jean-Christophe; Pihlstrøm, Lasse; van Nimwegen, Marlies; Smolensky, Luba; Amondikar, Ninad; Hutten, Samantha J; Frasier, Mark; Nguyen, Khanh-Dung H; Rick, Jacqueline; Eberly, Shirley; Faghri, Faraz; Auinger, Peggy; Scott, Kirsten M; Wijeyekoon, Ruwani; Van Deerlin, Vivianna M; Hernandez, Dena G; Gibbs, Raphael J; Day-Williams, Aaron G; Brice, Alexis; Alves, Guido; Noyce, Alastair J; Tysnes, Ole-Bjørn; Evans, Jonathan R; Breen, David P; Estrada, Karol; Wegel, Claire E; Danjou, Fabrice; Simon, David K; Andreassen, Ole A; Ravina, Bernard; Toft, Mathias; Heutink, Peter; Bloem, Bastiaan R; Weintraub, Daniel; Barker, Roger A; Williams-Gray, Caroline H; van de Warrenburg, Bart P; Van Hilten, Jacobus J; Scherzer, Clemens R; Singleton, Andrew B; Nalls, Mike A.
Afiliação
  • Iwaki H; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Blauwendraat C; Data Tecnica International, Glen Echo, Maryland, USA.
  • Leonard HL; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Makarious MB; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Kim JJ; Data Tecnica International, Glen Echo, Maryland, USA.
  • Liu G; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Maple-Grødem J; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Corvol JC; School of Medicine, Sun Yat-sen University, Guangzhou, China.
  • Pihlstrøm L; Advanced Center for Parkinson's Disease Research, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • van Nimwegen M; Precision Neurology Program, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Smolensky L; The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
  • Amondikar N; Department of Chemistry, Bioscience and Environmental Engineering, University in Stavanger, Stavanger, Norway.
  • Hutten SJ; Assistance-Publique Hôpitaux de Paris, ICM, INSERM UMRS 1127, CNRS 7225, ICM, Department of Neurology and CIC Neurosciences, Pitié-Salpêtrière Hospital, Paris, France.
  • Frasier M; Department of Neurology, Oslo University Hospital, Oslo, Norway.
  • Nguyen KH; Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Rick J; The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
  • Eberly S; The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
  • Faghri F; The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
  • Auinger P; The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
  • Scott KM; Translational Genome Sciences, Biogen, Cambridge, Massachusetts, USA.
  • Wijeyekoon R; Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Van Deerlin VM; Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA.
  • Hernandez DG; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Gibbs RJ; Department of Neurology, Center for Health + Technology, University of Rochester, Rochester, New York, USA.
  • Day-Williams AG; Department of Clinical Neurosciences, University of Cambridge, John van Geest Centre for Brain Repair, Cambridge, UK.
  • Brice A; Department of Clinical Neurosciences, University of Cambridge, John van Geest Centre for Brain Repair, Cambridge, UK.
  • Alves G; Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Noyce AJ; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Tysnes OB; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
  • Evans JR; Flagship Labs 60 Inc, Cambridge, Massachusetts, USA.
  • Breen DP; Statistical Genetics, Biogen, Cambridge, Massachusetts, USA.
  • Estrada K; Institut du cerveau et de la moelle épinière ICM, Paris, France.
  • Wegel CE; Sorbonne Université SU, Paris, France.
  • Danjou F; INSERM UMR1127, Paris, France.
  • Simon DK; The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway.
  • Andreassen OA; Department of Chemistry, Bioscience and Environmental Engineering, University in Stavanger, Stavanger, Norway.
  • Ravina B; Department of Neurology, Stavanger University Hospital, Stavanger, Norway.
  • Toft M; Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
  • Heutink P; Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK.
  • Bloem BR; Department of Neurology, Haukeland University Hospital, Bergen, Norway.
  • Weintraub D; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • Barker RA; Department of Neurology, Nottingham University NHS Trust, Nottingham, UK.
  • Williams-Gray CH; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK.
  • van de Warrenburg BP; Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK.
  • Van Hilten JJ; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
  • Scherzer CR; Translational Genome Sciences, Biogen, Cambridge, Massachusetts, USA.
  • Singleton AB; Department of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana, USA.
  • Nalls MA; Institut du cerveau et de la moelle épinière ICM, Paris, France.
Mov Disord ; 36(1): 106-117, 2021 01.
Article em En | MEDLINE | ID: mdl-33002231
ABSTRACT

BACKGROUND:

Previous studies reported various symptoms of Parkinson's disease (PD) associated with sex. Some were conflicting or confirmed in only one study.

OBJECTIVES:

We examined sex associations to PD phenotypes cross-sectionally and longitudinally in large-scale data.

METHODS:

We tested 40 clinical phenotypes, using longitudinal, clinic-based patient cohorts, consisting of 5946 patients, with a median follow-up of 3.1 years. For continuous outcomes, we used linear regressions at baseline to test sex-associated differences in presentation, and linear mixed-effects models to test sex-associated differences in progression. For binomial outcomes, we used logistic regression models at baseline and Cox regression models for survival analyses. We adjusted for age, disease duration, and medication use. In the secondary analyses, data from 17 719 PD patients and 7588 non-PD participants from an online-only, self-assessment PD cohort were cross-sectionally evaluated to determine whether the sex-associated differences identified in the primary analyses were consistent and unique to PD.

RESULTS:

Female PD patients had a higher risk of developing dyskinesia early during the follow-up period, with a slower progression in activities of daily living difficulties, and a lower risk of developing cognitive impairments compared with male patients. The findings in the longitudinal, clinic-based cohorts were mostly consistent with the results of the online-only cohort.

CONCLUSIONS:

We observed sex-associated contributions to PD heterogeneity. These results highlight the necessity of future research to determine the underlying mechanisms and importance of personalized clinical management. © 2020 International Parkinson and Movement Disorder Society.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Disfunção Cognitiva Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Disfunção Cognitiva Idioma: En Ano de publicação: 2021 Tipo de documento: Article